stk-012

STK-012 is a first-in-class, engineered α/β-biased interleukin-2 (IL-2) partial agonist developed by Synthekine. It is designed to selectively stimulate CD25+ antigen-activated T cells, which are associated with potent anti-tumor activity, while avoiding broad stimulation of other lymphocytes such as natural killer (NK) cells that are linked to IL-2 toxicity. This selectivity aims to enhance anti-tumor efficacy and reduce the severe toxicities typically seen with traditional IL-2 therapies. STK-012 has demonstrated dose-dependent induction of pro-inflammatory cytokines and selective proliferation of antigen-specific T cells in early clinical trials for advanced solid tumors, including renal cell carcinoma and non-small cell lung cancer. The drug has shown a favorable safety profile without dose-limiting toxicities or capillary leak syndrome in Phase 1a studies[1][5][6][7][9].